» Articles » PMID: 39236039

Trends of Primary Liver Cancer Incidence and Mortality in the United States: A Population-based Study over the Last Four Decades

Overview
Journal PLoS One
Date 2024 Sep 5
PMID 39236039
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary liver cancer is the third leading cause of cancer deaths worldwide and has one of the worst 5-year survival rates. This study examines US primary liver cancer incidence and incidence-based mortality trends over four decades.

Research Design And Methods: The SEER-9 registry was used to study primary liver cancer cases from 1978 to 2018. The incidence and mortality rates were calculated based on gender, age, race, and stage of diagnosis. Joinpoint regression software was used to calculate the annual percent change.

Results: The overall incidence rate of primary liver cancer from 1978 to 2018 increased by 2.71%/year (p<0.001). Rates in patients <50 years old began to fall in 2002 at a rate of -3.62%/year (p<0.001). Similarly, the incidence-based mortality rates for primary liver cancer increased by 2.15%/year (p<0.001). Whereas Whites incidence-based mortality rates began to plateau in 2012 (0.18%/year; p = 0.84), Blacks rates have declined since 2010 (-2.93%/year; p = 0.03), and Asian rates have declined since 1999 (-1.30%/year; p<0.001).

Conclusion: While the overall primary liver cancer incidence and incidence-based mortality have been increasing over the last four decades, there was an observed decline in incidence and incidence-based mortality in recent years, especially among at-risk subgroups.

Citing Articles

Information overload, financial constraints, and psychological burdens are among the barriers faced by marginalized groups seeking curative treatments for HCC.

Nephew L, Moore C, Garcia N, Parks L, McKay A, Strauss A Hepatol Commun. 2025; 9(3).

PMID: 40008878 PMC: 11868430. DOI: 10.1097/HC9.0000000000000660.


Macrotrabecular-Massive Hepatocellular Carcinoma: A Case Report.

Eftimie Spitz R, Manole S, Surdea-Blaga T, Caraiani C, Burz C Cureus. 2025; 16(12):e75989.

PMID: 39835031 PMC: 11743052. DOI: 10.7759/cureus.75989.


Identification of a senescence-related transcriptional signature to uncover molecular subtypes and key genes in hepatocellular carcinoma.

He X, Liu F, Gong Q PLoS One. 2024; 19(10):e0311696.

PMID: 39383169 PMC: 11463828. DOI: 10.1371/journal.pone.0311696.

References
1.
Yang M, Parikh N, Liu H, Wu E, Rao H, Feng B . Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. Sci Rep. 2020; 10(1):20922. PMC: 7708980. DOI: 10.1038/s41598-020-77515-y. View

2.
Singal A, Rich N, Mehta N, Branch A, Pillai A, Hoteit M . Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019; 157(5):1253-1263.e2. PMC: 6815711. DOI: 10.1053/j.gastro.2019.07.040. View

3.
Rinella M . Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22):2263-73. DOI: 10.1001/jama.2015.5370. View

4.
Liaw Y, Sung J, Chow W, Farrell G, Lee C, Yuen H . Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15):1521-31. DOI: 10.1056/NEJMoa033364. View

5.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View